3073 related articles for article (PubMed ID: 19204204)
1. Supervised risk predictor of breast cancer based on intrinsic subtypes.
Parker JS; Mullins M; Cheang MC; Leung S; Voduc D; Vickery T; Davies S; Fauron C; He X; Hu Z; Quackenbush JF; Stijleman IJ; Palazzo J; Marron JS; Nobel AB; Mardis E; Nielsen TO; Ellis MJ; Perou CM; Bernard PS
J Clin Oncol; 2009 Mar; 27(8):1160-7. PubMed ID: 19204204
[TBL] [Abstract][Full Text] [Related]
2. Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes.
Parker JS; Mullins M; Cheang MCU; Leung S; Voduc D; Vickery T; Davies S; Fauron C; He X; Hu Z; Quackenbush JF; Stijleman IJ; Palazzo J; Marron JS; Nobel AB; Mardis E; Nielsen TO; Ellis MJ; Perou CM; Bernard PS
J Clin Oncol; 2023 Sep; 41(26):4192-4199. PubMed ID: 37672882
[TBL] [Abstract][Full Text] [Related]
3. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of the intrinsic molecular subtypes of breast cancer.
Prat A; Pineda E; Adamo B; Galván P; Fernández A; Gaba L; Díez M; Viladot M; Arance A; Muñoz M
Breast; 2015 Nov; 24 Suppl 2():S26-35. PubMed ID: 26253814
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
6. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
Matsubara N; Mukai H; Fujii S; Wada N
Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
[TBL] [Abstract][Full Text] [Related]
7. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen.
Chia SK; Bramwell VH; Tu D; Shepherd LE; Jiang S; Vickery T; Mardis E; Leung S; Ung K; Pritchard KI; Parker JS; Bernard PS; Perou CM; Ellis MJ; Nielsen TO
Clin Cancer Res; 2012 Aug; 18(16):4465-72. PubMed ID: 22711706
[TBL] [Abstract][Full Text] [Related]
8. Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.
Gluz O; Liedtke C; Huober J; Peyro-Saint-Paul H; Kates RE; Kreipe HH; Hartmann A; Pelz E; Erber R; Mohrmann S; Möbus V; Augustin D; Hoffmann G; Thomssen C; Jänicke F; Kiechle M; Wallwiener D; Kuhn W; Nitz U; Harbeck N
Ann Oncol; 2016 Jun; 27(6):1035-1040. PubMed ID: 27022068
[TBL] [Abstract][Full Text] [Related]
9. Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics.
Sweeney C; Bernard PS; Factor RE; Kwan ML; Habel LA; Quesenberry CP; Shakespear K; Weltzien EK; Stijleman IJ; Davis CA; Ebbert MT; Castillo A; Kushi LH; Caan BJ
Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):714-24. PubMed ID: 24521995
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive parameters in breast pathology: a pathologist's primer.
Allison KH
Mod Pathol; 2021 Jan; 34(Suppl 1):94-106. PubMed ID: 33154551
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
12. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay.
Perreard L; Fan C; Quackenbush JF; Mullins M; Gauthier NP; Nelson E; Mone M; Hansen H; Buys SS; Rasmussen K; Orrico AR; Dreher D; Walters R; Parker J; Hu Z; He X; Palazzo JP; Olopade OI; Szabo A; Perou CM; Bernard PS
Breast Cancer Res; 2006; 8(2):R23. PubMed ID: 16626501
[TBL] [Abstract][Full Text] [Related]
13. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
[TBL] [Abstract][Full Text] [Related]
15. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
16. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.
Bonnefoi H; Litière S; Piccart M; MacGrogan G; Fumoleau P; Brain E; Petit T; Rouanet P; Jassem J; Moldovan C; Bodmer A; Zaman K; Cufer T; Campone M; Luporsi E; Malmström P; Werutsky G; Bogaerts J; Bergh J; Cameron DA;
Ann Oncol; 2014 Jun; 25(6):1128-36. PubMed ID: 24618153
[TBL] [Abstract][Full Text] [Related]
17. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
18. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.
Nielsen TO; Parker JS; Leung S; Voduc D; Ebbert M; Vickery T; Davies SR; Snider J; Stijleman IJ; Reed J; Cheang MC; Mardis ER; Perou CM; Bernard PS; Ellis MJ
Clin Cancer Res; 2010 Nov; 16(21):5222-32. PubMed ID: 20837693
[TBL] [Abstract][Full Text] [Related]
19. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.
Hugh J; Hanson J; Cheang MC; Nielsen TO; Perou CM; Dumontet C; Reed J; Krajewska M; Treilleux I; Rupin M; Magherini E; Mackey J; Martin M; Vogel C
J Clin Oncol; 2009 Mar; 27(8):1168-76. PubMed ID: 19204205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
